Richard A Ward

List of Publications by Year
in descending order

42 papers	4,217 citations	304743 22 h-index	265206 42 g-index
45 all docs	45 docs citations	45 times ranked	6842 citing authors

#	Article	IF	Citations
1	AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer. Cancer Discovery, 2014, 4, 1046-1061.	9.4	1,655
2	Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor. Journal of Medicinal Chemistry, 2014, 57, 8249-8267.	6.4	454
3	Characterization of VPS34-IN1, a selective inhibitor of Vps34, reveals that the phosphatidylinositol 3-phosphate-binding SGK3 protein kinase is a downstream target of class III phosphoinositide 3-kinase. Biochemical Journal, 2014, 463, 413-427.	3.7	233
4	Structure-based design of targeted covalent inhibitors. Chemical Society Reviews, 2018, 47, 3816-3830.	38.1	229
5	Challenges and Opportunities in Cancer Drug Resistance. Chemical Reviews, 2021, 121, 3297-3351.	47.7	203
6	Structure- and Reactivity-Based Development of Covalent Inhibitors of the Activating and Gatekeeper Mutant Forms of the Epidermal Growth Factor Receptor (EGFR). Journal of Medicinal Chemistry, 2013, 56, 7025-7048.	6.4	201
7	Design and Synthesis of Novel Lactate Dehydrogenase A Inhibitors by Fragment-Based Lead Generation. Journal of Medicinal Chemistry, 2012, 55, 3285-3306.	6.4	144
8	Expanding the Armory: Predicting and Tuning Covalent Warhead Reactivity. Journal of Chemical Information and Modeling, 2017, 57, 3124-3137.	5.4	115
9	Preclinical Comparison of the Blood–brain barrier Permeability of Osimertinib with Other EGFR TKIs. Clinical Cancer Research, 2021, 27, 189-201.	7.0	106
10	Structure-Guided Design of Highly Selective and Potent Covalent Inhibitors of ERK1/2. Journal of Medicinal Chemistry, 2015, 58, 4790-4801.	6.4	84
11	Comparison of the EGFR resistance mutation profiles generated by EGFR-targeted tyrosine kinase inhibitors and the impact of drug combinations. Biochemical Journal, 2008, 415, 197-206.	3.7	83
12	Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions. Molecular Cancer Therapeutics, 2018, 17, 885-896.	4.1	80
13	Identification and Characterization of Dual Inhibitors of the USP25/28 Deubiquitinating Enzyme Subfamily. ACS Chemical Biology, 2017, 12, 3113-3125.	3.4	68
14	Discovery of a Potent and Selective Oral Inhibitor of ERK1/2 (AZD0364) That Is Efficacious in Both Monotherapy and Combination Therapy in Models of Nonsmall Cell Lung Cancer (NSCLC). Journal of Medicinal Chemistry, 2019, 62, 11004-11018.	6.4	44
15	Alkynyl Benzoxazines and Dihydroquinazolines as Cysteine Targeting Covalent Warheads and Their Application in Identification of Selective Irreversible Kinase Inhibitors. Journal of the American Chemical Society, 2020, 142, 10358-10372.	13.7	44
16	Structure-Guided Discovery of Potent and Selective Inhibitors of ERK1/2 from a Modestly Active and Promiscuous Chemical Start Point. Journal of Medicinal Chemistry, 2017, 60, 3438-3450.	6.4	42
17	Systematic Enumeration of Heteroaromatic Ring Systems as Reagents for Use in Medicinal Chemistry. Journal of Medicinal Chemistry, 2011, 54, 4670-4677.	6.4	35
18	Insight into the Therapeutic Selectivity of the Irreversible EGFR Tyrosine Kinase Inhibitor Osimertinib through Enzyme Kinetic Studies. Biochemistry, 2020, 59, 1428-1441.	2.5	35

#	Article	IF	Citations
19	Structure-Based Virtual Screening for Low Molecular Weight Chemical Starting Points for Dipeptidyl Peptidase IV Inhibitors. Journal of Medicinal Chemistry, 2005, 48, 6991-6996.	6.4	34
20	The structure-guided discovery of osimertinib: the first U.S. FDA approved mutant selective inhibitor of EGFR T790M. MedChemComm, 2017, 8, 820-822.	3.4	33
21	Rapid Generation of a High Quality Lead for Transforming Growth Factor-β (TGF-β) Type I Receptor (ALK5). Journal of Medicinal Chemistry, 2009, 52, 7901-7905.	6.4	30
22	Identification of DYRK1B as a substrate of ERK1/2 and characterisation of the kinase activity of DYRK1B mutants from cancer and metabolic syndrome. Cellular and Molecular Life Sciences, 2016, 73, 883-900.	5.4	25
23	Cysteine protease inhibition by nitrile-based inhibitors: a computational study. Frontiers in Chemistry, 2013, 1, 39.	3.6	24
24	Structural basis of the effect of activating mutations on the EGF receptor. ELife, 2021, 10, .	6.0	24
25	ParaMol: A Package for Automatic Parameterization of Molecular Mechanics Force Fields. Journal of Chemical Information and Modeling, 2021, 61, 2026-2047.	5.4	22
26	Optimization of Highly Kinase Selective Bis-anilino Pyrimidine PAK1 Inhibitors. ACS Medicinal Chemistry Letters, 2016, 7, 1118-1123.	2.8	21
27	Enzymatic Characterisation of USP7 Deubiquitinating activity and Inhibition. Cell Biochemistry and Biophysics, 2011, 60, 99-111.	1.8	20
28	Discovery and Optimization of a Novel Series of Dyrk1B Kinase Inhibitors To Explore a MEK Resistance Hypothesis. Journal of Medicinal Chemistry, 2015, 58, 2834-2844.	6.4	19
29	Identification and optimisation of 7-azaindole PAK1 inhibitors with improved potency and kinase selectivity. MedChemComm, 2014, 5, 1533-1539.	3.4	15
30	A High-Throughput Screening Triage Workflow to Authenticate a Novel Series of PFKFB3 Inhibitors. SLAS Discovery, 2018, 23, 11-22.	2.7	13
31	AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in <i>KRAS</i>-Mutant Tumor Models when Combined with the MEK Inhibitor, Selumetinib. Molecular Cancer Therapeutics, 2021, 20, 238-249.	4.1	13
32	Potent and Selective Inhibitors of the Epidermal Growth Factor Receptor to Overcome C797S-Mediated Resistance. Journal of Medicinal Chemistry, 2021, 64, 13704-13718.	6.4	13
33	Using protein-ligand docking to assess the chemical tractability of inhibiting a protein target. Journal of Molecular Modeling, 2010, 16, 1833-1843.	1.8	12
34	Predicting protein–ligand binding affinity and correcting crystal structures with quantum mechanical calculations: lactate dehydrogenase A. Chemical Science, 2019, 10, 2218-2227.	7.4	11
35	Data-mining patent literature for novel chemical reagents for use in medicinal chemistry design. MedChemComm, 2010, 1, 331.	3.4	9
36	High throughput sequencing and RT-qPCR assay reveal the presence of rose cryptic virus-1 in the United Kingdom. Journal of Plant Pathology, 2019, 101, 1171-1175.	1.2	7

#	Article	IF	Citations
37	Toward the Comprehensive Systematic Enumeration and Synthesis of Novel Kinase Inhibitors Based on a 4-Anilinoquinazoline Binding Mode. Journal of Chemical Information and Modeling, 2010, 50, 525-533.	5.4	6
38	Evaluation of Novel Synthetic Methods for the Preparation of the Sodium Channel Inhibitor, GW273225X. Organic Process Research and Development, 2014, 18, 82-88.	2.7	6
39	Generation of Quantum Configurational Ensembles Using Approximate Potentials. Journal of Chemical Theory and Computation, 2021, 17, 7021-7042.	5.3	2
40	Drugging the undruggable: a computational chemist's view of KRASG12C. RSC Medicinal Chemistry, 2021, 12, 609-614.	3.9	1
41	Abstract 4813: Comparative activity profiling of tyrosine kinase inhibitors (TKIs) against exon 20 insertions and the wild-type form of epidermal growth factor receptor (EGFR). Cancer Research, 2019, 79, 4813-4813.	0.9	1
42	Modeling Covalent Protein-Ligand Interactions. , 2021, , 174-189.		0